



Attorney Docket No. 249.P1C2  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Becker et al.

Serial No.: 10/798,692

Group No.: unassigned

Filed: March 11, 2004

Examiner: unassigned

For: PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES

Commissioner for Patents  
Mail Stop Missing Parts  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN  
THREE MONTHS OF FILING OR BEFORE MAILING OF  
FIRST OFFICE ACTION (37 CFR 1.97 (b))**

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(check and complete appropriate item below);

☒ 37 CFR 1.8 (a)  
with sufficient postage as  
first class mail

or

☐ 37 CFR 1.10  
as "Express Mail Post  
Office to Addressee" Mailing  
Label  
No. \_\_\_\_\_

Date:

September 14, 2004

Robin Torres

(Type or print name of person mailing paper)

Robin Torres

(Signature of person mailing paper)




**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 35,071

Tel. No.: (650 ) 522-5569

  
\_\_\_\_\_  
**SIGNATURE OF ATTORNEY**

Mark L. Bosse

\_\_\_\_\_  
Type or print name of attorney

Gilead Sciences, Inc.

\_\_\_\_\_  
333 Lakeside Drive

\_\_\_\_\_  
P.O. Address

\_\_\_\_\_  
Foster City, CA 94404

## Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of the references has any bearing under United States Law.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Section 3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Serial No. 10/354,207 , filed on January 28, 2003

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 35,071

Tel. No.: (650 ) 522-5569

  
\_\_\_\_\_  
**SIGNATURE OF ATTORNEY**

Mark L. Bosse

\_\_\_\_\_  
Type or print name of attorney

Gilead Sciences, Inc.

\_\_\_\_\_  
333 Lakeside Drive

\_\_\_\_\_  
P.O. Address

Foster City, CA 94404



Attorney Docket No. 249.P1C2  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Becker et al.

Serial No.: 10/798,692

Group No.: unassigned

Filed: March 11, 2004

Examiner: unassigned

For: PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES

Commissioner for Patents  
Mail Stop Missing Parts  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (modified)**

**List of Sections Forming Part of This Information Disclosure Statement.**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Identification of Prior Application in Which Listed Information Was Already Cited.

---

**CERTIFICATE OF MAILING**

I hereby certify that this Information Disclosure Statement (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

☒ 37 CFR 1.8 (a)  
with sufficient postage as  
first class mail

or

☐ 37 CFR 1.10  
as "Express Mail Post  
Office to Addressee" Mailing  
Label  
No. \_\_\_\_\_

Date: \_\_\_\_\_

September 14, 2004

Robin Torres

(Type or print name of person mailing paper)

Robin Torres  
(Signature of person mailing paper)



FORM PTO-1449

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE****INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(37 CFR 1.98(b))

ATTY DOCKET NO.: 249.P1C2 SERIAL NO.: 10/798,692

APPLICANT: Becker et al.

FILING DATE: 3/11/04

GROUP ART UNIT:

**U.S. PATENT DOCUMENTS**

Examiner initials	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class/ Subclass	Filing Date
	5,053,215	10-01-1991	Rand et al		05-26-1988
	5,413,996	05-09-1995	Bodor, Nicholas		10-16-1992
	5,624,894	04-29-1997	Bodor, Nicholas		04-27-1995
	5,627,165	05-06-1997	Glazier, Arnold		09-23-1994
	5,663,159	09-02-1997	STARRETT JR. ET AL		10-11-1994
	5,792,756	08-11-1998	STARRETT JR. ET AL		06-07-1995
	5,798,340	08-25-1998	BISCHOFBERGER ET AL		09-16-1994
	5,977,061	11-02-1999	Holy et al.		04-21-1995
	5,977,089	11-12-1999	Arimilli et al.		11-06-1998
	6,169,078	01-02-2001	Hughes et al		05-12-1998
	6,245,750	06-12-2001	Shepard, Michael		01-22-1999
	6,339,151	01-15-2002	Shepard et al		01-22-1999
	6,348,185	02-19-2002	Piwnica-Worms, David		06-18-1999
	6,355,629	03-12-2002	Kozak		02-06-2001
	6,436,437	08-20-2002	Yatvin et al		02-15-2000
	US2001/0031873	10-18-2001	Greenwald et al		01-12-2001
	US2002/0120100A1	08-29-2002	Bonny		10-15-2001


**FOREIGN PATENT DOCUMENTS**

Examiner initials	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class/ Subclass	Translation Yes/No
	EP 0 336 364 A2	10-11-1989	NEORX CORPORATION		
	EP 0 481 214 A1	04-22-1992	BRISTOL-MEYERS SQUIBB COMPANY		
	WO 00/18775	04-06-2000			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(37 CFR 1.98(b))

ATTY DOCKET NO.: 249.P1C2 SERIAL NO.: 10/798,692

APPLICANT: Becker et al.

FILING DATE: 3/11/04

GROUP ART UNIT:

Examiner initials	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class/ Subclass	Translation Yes/No
	WO 96/29336	09-26-1996	Medical Research Council		
	WO 96/33200	10-24-1996	Ustav Organicke Chemie A Biochemie Akademie Ved		
	WO 96/37503	11-28-1996	GENTA INCORPORATED		


## OTHER DOCUMENTS

Examiner initials	Article
	Aarons et al., "Pharmacokinetic Evaluation of Site-Specific Drug Delivery Systems", 12:121-126, Novel Drug Delivery and Its Therapeutic Application (John Wiley & Sons), 1989
	Banerjee et al., "Design of Prodrugs Based on Enzyme-Substrate Specificity", Chapter 2, pp. 118-121, DESIGN OF PRODRUGS, 1985
	Brunel et al., "A Practical Method for the Large-Scale Synthesis of Diastereomerically Pure (2R,5S)-3-Phenyl-2-(8-quinolinoxy)-1,3-diaza-2-phosphabicyclo-[3.3.0]-octane Ligand (QUIPHOS)", 64:8940-8942, J ORG CHEM, 1999
	Bundgaard, H., "Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities", Chapter 1, pp. 70-92, DESIGN OF PRODRUGS, 1985
	Chapman et al., "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340", 20(4-7):621-628, Nucleosides, Nucleotides & Nucleic Acids, 2001
	Connors, T.A., "Prodrugs in Cancer Chemotherapy", Chapter 9, pp. 291-316, DESIGN OF PRODRUGS, 1985
	Jones, Geraint, "Decreased Toxicity and Adverse Reactions via Prodrugs", Chapter 6:pp. 199-241, DESIGN OF PRODRUGS, 1985
	Kumar et al., "Heterocalixarenes. 1. Calix[2]uracil[2]arene: Synthesis, X-ray Structure, Conformational Analysis, and Binding Character", 64:7717-7726, J ORG CHEM, 1999
	McGuigan et al., "Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT", 17:311-321, ANTIVIRAL RES, 1992
	McGuigan et al., "Aryl Phosphate Derivatives of AZT Inhibit HIV Replication in Cells Where the Nucleoside is Poorly Active", 2(7):701-704, BIOORG MED CHEM LETT, 1992
	McGuigan et al., "Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase", 351:11-14, FEBS, 1994
	McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT", 36:1048-1052, J MED CHEM, 1993

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE****INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(37 CFR 1.98(b))

ATTY DOCKET NO.: 249.P1C2 SERIAL NO.: 10/798,692

APPLICANT: Becker et al.

FILING DATE: 3/11/04

GROUP ART UNIT:

Examiner initials	Article
	McGuigan et al., "Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region", 7(1):31-36, ANTIVIRAL CHEM & CHEMO, 1996
	Notari, Robert E., "Pharmacokinetic Aspects of Prodrug Design and Evaluation", Chapter 3, pp. 135-156, DESIGN OF PRODRUGS, 1985
	Oliyai et al., "Aryl Ester Prodrugs of Cyclic HPMP. I: Physicochemical Characterization and In Vitro Biological Stability", 16(11):1687-1693, PHARM RES, 1999
	Siddiqui et al., "Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR", 42:4122-4128, PHARM RES, 1999
	Starrett et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)", 37:1857-1864, J MED CHEM, 1994
	Stella et al., "Site-Specific Drug Delivery via Prodrugs", Chapter 5, pp. 177-198, DESIGN OF PRODRUGS, 1985
	Stella, Valentino J., "Prodrugs and Site-Specific Drug Delivery", 23(12):1275-1282, J MED CHEM, December 1980
	Strube et al., "Comparison of Batch Elution and Continuous Simulated Moving Bed Chromatography", 2:305-319, ORGANIC PROCESS RESEARCH & DEVELOPMENT, 1998

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.